|Bid||114.09 x 1800|
|Ask||114.19 x 900|
|Day's Range||111.86 - 114.67|
|52 Week Range||67.98 - 162.13|
|Beta (5Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||190.94|
Shares of GW Pharmaceuticals PLC slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coronavirus pandemic. The U.K. company is the only one to have U.S. Food and Drug Administration approval for a cannabis-based drug, Epidiolex, a treatment for severe forms of childhood epilepsy. The company posted a loss of $8.8 million, or 2 cents a share, for the quarter, after income of $79.7 million in the year-earlier period. Revenue rose to $121.3 million from $72.0 million. "We were pleased with the strength of U.S. Epidiolex sales in the second quarter in spite of the COVID-19 pandemic," Chief Executive Justin Gover said in a statement. Epidiolex sales came to $117.7 million. "Further, the recent approval and imminent launch of Epidiolex for the treatment of seizures associated with TSC provides a meaningful new opportunity to accelerate momentum through the second half of 2020 and beyond," he said. Leerink analyst Marc Goodman said the numbers were "solid" coming in the midst of the pandemic, and in line with management's guidance from its first-quarter conference call. "... we think GW executed through the volatility well, and thus we are surprised that the stock is down ~10% in the after market," he wrote in a Thursday note to clients. Leerink rates the stock as outperform with a $190 stock price target. Shares have gained 11% in the year to date, as the S&P 500 has gained 3.6%.
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) * ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Biocept Inc (NASDAQ: BIOC) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) * DarioHealth Corp (NASDAQ: DRIO) * Denali Therapeutics Inc (NASDAQ: DNLI)( announced selection of candidate to enter Phase 3 study in Parkinson's disease) * Editas Medicine Inc (NASDAQ: EDIT)(moved on M&A speculation) * Emergent Biosolutions Inc (NYSE: EBS) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Harvard Bioscience, Inc. (NASDAQ: HBIO) * ITAMAR MED LTD/S ADR (NASDAQ: ITMR) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Natera Inc (NASDAQ: NTRA) * PDL BioPharma Inc (NASDAQ: PDLI) * Sangamo Therapeutics Inc (NASDAQ: SGMO) (reacted to its second-quarter results) * Shockwave Medical Inc (NASDAQ: SWAV) * SurModics, Inc. (NASDAQ: SRDX)(reacted to its second-quarter results) * Twist Bioscience Corp (NASDAQ: TWST) * Unity Biotechnology Inc (NASDAQ: UBX) * Zoetis Inc (NYSE: ZTS) (reacted to its second-quarter results)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 6) * Nkarta Inc (NASDAQ: NKTX) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX)(announced its second-quarter results)Stocks In Focus Zosano Clinches Distribution Deal For Investigational Migraine Patch Zosano Pharma Corp (NASDAQ: ZSAN) said it has partnered with Eversana commercialize and distribute Qtrypta in the U.S. Qtrypta is Zosano's transdermal microneedle product candidate for the acute treatment of migraine. In March, the FDA accepted a NDA for Qtrypta and granted a PDUFA goal date of October 20. If approved, Qtrypta would be the first and only microneedle patch indicated for the acute treatment of migraine, Zosano said.The stock jumped 31.62% to $1.79 in after-hours trading.FDA Approves ViiV's Two-Drug Combo Treatment ViiV Healthcare, majority owned by GlaxoSmithKline plc (NYSE: GSK) and Pfizer Inc. (NYSE: PFE), said the FDA approved Dovato - dolutegravir/lamivudine - as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral regimen in adults who are virologically suppressed on a stable ARV regimen with no history of treatment failure and no known resistance to the individual components of Dovato.Novavax Strikes Coronavirus Vaccine Agreements With Takeda, India's Serum Institute Novavax, Inc. (NASDAQ: NVAX) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced a partnership for the development of the former's COVID 19 vaccine candidate - NVX CoV2373 - in Japan.Takeda is to receive funding from the Government of Japan's Ministry of Health, Labour and Welfare to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year.Novavax will be entitled to receive payments based on the achievement of certain development and commercial milestones, as well as a portion of proceeds from the vaccine.Separately, Novavax announced a license agreement with Serum Institute of India Private Limited for the development and commercialization of NVX CoV237 in low- and middle-income countries and India. The companies hope to make available a minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countries.Novavax shares were adding 2.21% to $171.20, while Takeda was gaining 1.81% to $18.52.Co-Diagnostics' COVID-19 Tests Authorized In Australia Co-Diagnostics Inc (NASDAQ: CODX) said the Logix Smart COVID-19 for use in detecting SARS-CoV-2, the virus that causes COVID-19, has been authorized for use in Australian.The stock was gaining 3.25% to $27 in premarket trading.Roche's Tencentriq-chemo Combo Flunks Breast Cancer Study Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the Phase 3 IMpassion131 study, evaluating Tecentriq in combination with paclitaxel, in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival for first-line treatment of people with metastatic triple-negative breast cancer, in the PD-L1-positive population.CytoDyn To Request Pre-submission Meetings for Approval of Leronlimab For AIDS and COVID-19 In U.K. CytoDyn Inc (OTC: CYDY) said it will submit requests for pre-submission meetings in the U.K. for leronlimab as a HIV treatment in combination with HAART for highly treatment experienced HIV patients, as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate symptoms.Earnings PDL Biopharma said its second-quarter revenues fell from $7.5 million in 2019 to $5.2 million in 2020. The loss per share widened from 43 cents to 4 cents, while analysts estimated a profit of 10 cents per share.The stock plunged 13.84% to $3.02 in after-hours trading.Adamas Pharmaceuticals Inc's (NASDAQ: ADMS) second-quarter revenues climbed from $12.69 million in 2019 to $18.79 million in 2020, with Gocovri contributing $18 million, up 41% year-over-year. The net loss per share narrowed from 90 cents to 37 cents. Analysts had estimated a wider loss of 61 cents per share.The stock jumped 18.77% to $3.10 in after-hours trading.Coherus Biosciences Inc (NASDAQ: CHRS) reported an increase in its second-quarter revenues from $83.43 million to $135.67 million, and earnings per share improved from 32 cents to 70 cents, while analysts expected earnings of 33 cents per share.In after-hours trading, the stock advanced 13.10% to $19.69.Illumina, Inc.'s (NASDAQ: ILMN) second-quarter revenues fell 25% year-over-year to $633 million, and non-GAAP earnings per share fell from $1.99 to 32 cents.View more earnings on IBBThe stock slid 12.10% to $351 in after-hours trading.GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported a year-over-year increase in second-quarter revenues from $72 million in 2019 to $121.3 million in 2020, with Epidiolex revenues at $117.7 million. The company reversed from a profit of 21 cents per share to a loss of 2 cents per share.The stock slipped 9.16% to $120 in after-hours trading.Applied DNA Sciences Inc's (NASDAQ: APDN) fiscal-year third-quarter revenues fell 79% year-over-year to $432,000, with the steep drop reflecting a decrease in licensing revenue in the cannabis industry as well as cannabis feasibility pilots. The loss per share narrowed from $1.55 to 72 cents, but was wider than the consensus loss estimate of 67 cents per share.The stock was retreating 15.68% to $9.25 in premarket trading Friday.Capricor Therapeutics Inc (NASDAQ: CAPR) reported a loss of 23 cents per share for its second quarter compared to a loss of 59 cents in the year-ago period. Analysts, on average, estimated a loss of 37 cents per share for the quarter."We are now well underway in animal studies and have seen promising results showing the mRNA vaccine is capable of generating an antibody response to multiple antigens expressed by COVID-19," the company said.The stock was declining 11.39% to $7 in premarket trading Friday.Vaxart Inc (NASDAQ: VXRT) reported second-quarter revenues of $532,000 in 2020 compared to $85,000 a year-ago. The loss per share narrowed from 39 cents to 12 cents, while analysts estimated a loss of 6 cents per share.Updating on the its coronavirus vaccine program, the company said it is now laser focused on preparing to enter a Phase 1 clinical trial with its lead COVID-19 vaccine candidate, which is an oral tablet.In premarket trading, the stock was adding 11.82% to $10.17.On The Radar PDUFA Dates Trevena Inc (NASDAQ: TRVN) has a tryst with the FDA, with respect to its NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.Earnings Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) Meridian Bioscience, Inc. (NASDAQ: VIVO) (before the market open) Ocular Therapeutix Inc (NASDAQ: OCUL) (before the market open) Mersana Therapeutics Inc (NASDAQ: MRSN) (before the market open) Jounce Therapeutics Inc (NASDAQ: JNCE) (before the market open) Replimune Group Inc (NASDAQ: REPL) (before the market open)Related Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates IPOsFreeline Therapeutics Holdings plc, a clinical-stage AAV-based gene therapy company focusing on inherited systemic debilitating diseases, priced its initial public offering, or IPO, of 8.824 million ADSs, representing 8.824 million ordinary shares, at $18 per share compared to the estimated price range of $16-$18, for generating gross proceeds of about $158.8 million. The shares will be listed on the Nasdaq under the ticker symbol FRLN. The offering is expected to close on Aug. 11.Checkmate Pharmaceuticals, Inc., a clinical stage oncology-focused biotech, said it priced its IPO of 5 million shares at $15, at the midpoint of the estimated price range of $14-$16. The company expects to raise gross proceeds of $75 million from the offering. The shares will be listed on the Nasdaq under the ticker symbol CMPI.See more from Benzinga * Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing * The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO * JPMorgan Turns Bullish On Novavax After Phase 1 Coronavirus Vaccine Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of GW Pharmaceuticals (NASDAQ:GWPH) increased 13.41% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were up 66.67% year over year to ($0.02), which beat the estimate of ($0.63).Revenue of $121,297,000 higher by 68.38% from the same period last year, which beat the estimate of $120,310,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Aug 06, 2020View more earnings on GWPHTime: 04:30 PMET Webcast URL: https://www.webcaster4.com/Webcast/Page/2013/35770Technicals 52-week high: $175.3552-week low: $67.98Price action over last quarter: Up 7.41%Company Profile GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.See more from Benzinga * Recap: Teradata Q2 Earnings * Recap: Verra Mobility Q2 Earnings * TrueCar: Q2 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.